PD-1 Fatigue: Cross-Labeling May Help Pare Checkpoint Inhibitor Pipeline

16 Aug 2018

• By Laura Helbling

US FDA encouraging developers to embrace cross-labeling rather than continue separate development of proprietary PD-1 agents, but agency sounds eager for any other good ideas to pare back the number of checkpoint inhibitors in development.

Watch gears up close — The US FDA wants firms' PD-1 trials to mesh together well.

The US FDA’s Office of Hematology and Oncology Products is encouraging policy makers and drug developers to focus on cross labeling as an alternative to independent development of still more PD-1/PD-L1 checkpoint inhibitors for oncology.

During a National Cancer Policy Forum workshop focusing on “Advancing Progress in the Development of Combination Cancer Therapies with...